almorexant Report issue

Small molecule Experimental
AACT MeSH PubChem

Active Ingredient History

NOW
  • Now
Almorexant (INN), also known by its development code ACT-078573, is an orexin antagonist, acting as a competitive antagonist of the OX1 and OX2 orexin receptors, which was being developed by the pharmaceutical companies Actelion and GSK for the treatment of insomnia. Development of the drug was abandoned in January 2011 due to concerns over the hepatic safety of almorexant after transient increases in liver enzymes were observed in trials.   Wikipedia

Chemistry

  • SMILES: CNC(=O)[C@@H](c1ccccc1)N1CCc2cc(OC)c(OC)cc2[C@@H]1CCc1ccc(C(F)(F)F)cc1
  • InChIKey: DKMACHNQISHMDN-RPLLCQBOSA-N
  • Mol. Mass: 512.57
  • ALogP: 5.74
  • ChEMBL Molecule:
    almorexant  
More Chemistry

Pharmacology

Alternative names

((2r)-2-((1s)-6,7-dimethoxy-1-(2-(4-trifluoromethylphenyl)-ethyl)-3,4-dihydro-1h-isoquinolin-2-yl)-n-methyl-2-phenylacetamide) | act-078573 | almorexant

Organizations (6)

Research & Development (6)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (5)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (5)


 

Pharmacokinetics (Phase 1)

Safety (Phase 1)

Sleep Disorders, Intrinsic (Phase 2)

Sleep Initiation and Maintenance Disorders (Phase 3)

Substance Abuse, Oral (Phase 1)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 6
  • # of Trial Organizations: 6

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue